clinical trial · NCT07221227
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
Non-alcoholic Fatty Liver DiseaseEfimosfermin alfaEfimosfermin alfaPlacebo
brief summary
The purpose of this study is to assess the safety and efficacy of efimosfermin alfa in the resolution of steatohepatitis and improvement of liver-related clinical outcome compared to placebo in individuals with MASH and biopsy-confirmed F2- or F3-stage fibrosis.
started
Oct 24, 2025
primary completion
Mar 29, 2028
completion
Dec 12, 2031
last updated
Jul 27, 2026
official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa in Participants With Biopsy-Confirmed F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-1)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol